


## p-Anisic acid-<sup>13</sup>C<sub>6</sub>

<b>Cat. No.:</b>	HY-N1394S
<b>CAS No.:</b>	1173022-97-3
<b>Molecular Formula:</b>	C <sub>2</sub> <sup>13</sup> C <sub>6</sub> H <sub>8</sub> O <sub>3</sub>
<b>Molecular Weight:</b>	158.1
<b>Target:</b>	Bacterial; Endogenous Metabolite; Isotope-Labeled Compounds
<b>Pathway:</b>	Anti-infection; Metabolic Enzyme/Protease; Others
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	p-Anisic acid- <sup>13</sup> C <sub>6</sub> is the <sup>13</sup> C-labeled p-Anisic acid. p-Anisic acid (4-Methoxybenzoic acid) is one of the isomers of anisic acid, with anti-bacterial and antiseptic properties[1].
<b>In Vitro</b>	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-216.
- [2]. DeWeerd K, et al. Metabolism of the 18O-methoxy substituent of 3-methoxybenzoic acid and other unlabeled methoxybenzoic acids by anaerobic bacteria. *Appl Environ Microbiol.* 1988 May;54(5):1237-42.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA